Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NP-G2-044
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novita to Present NP-G2-044 Phase 2 Data in Solid Tumors at AACR IO 2025
Details : NP-G2-044 is a novel small molecule that inhibits function of fascin. It is currently being investigated for advanced or metastatic solid tumor malignancies.
Product Name : NP-G2-044
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2025
Lead Product(s) : NP-G2-044
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable